Invivyd IVVD
NASDAQ IVVD
$0.83 +0.00 (+0.00%)
At close: Sep 4, 2026 · 4:00 PM EDT

Invivyd (IVVD) Change in Accured Expenses (2021 - 2025)

Invivyd's (IVVD) quarterly Change in Accured Expenses came in at -$6.0 million in Q4 2025, up 15.05% on a YoY basis from -$5.2 million in Q4 2024, and down 2296.81% quarter-over-quarter from -$251000.0 in Q3 2025.

Analysis

Invivyd (IVVD) Change in Accured Expenses (2021 - 2025) Analysis & Trends

Invivyd (IVVD) has reported Change in Accured Expenses for 5 consecutive years, with -$6.0 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 15.05% year-over-year to -$6.0 million; the trailing twelve-month figure through Dec 2025 stood at -$30.8 million (down 444.66% YoY), and the FY2025 full-year result was -$30.8 million, down 444.66% from the prior year.
  • Change in Accured Expenses declined to -$6.0 million in Q4 2025 per IVVD's latest filing, from -$251000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $31.9 million in Q3 2024 and bottomed at -$23.9 million in Q2 2022.
  • Historically, Change in Accured Expenses has averaged $687800.0 across 5 years, with a median of -$6.5 million in 2023.
  • The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses slumped 375.88% in 2022, then soared 436.58% in 2023.
  • Over 5 years, Change in Accured Expenses stood at $21.2 million in 2021, then plunged by 134.44% to -$7.3 million in 2022, then jumped by 436.58% to $24.6 million in 2023, then sank by 128.77% to -$7.1 million in 2024, then climbed by 15.05% to -$6.0 million in 2025.
  • According to Business Quant data, Change in Accured Expenses over the past three periods registered -$6.0 million, -$251000.0, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 852.00 Mn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 338.00 Mn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 222.50 Mn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 492.70 Mn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn -
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 11.00 Mn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 61.62 Mn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn -49.70 Mn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 68.82 Mn
10 Invivyd 244.65 Mn 84.57 Mn 13.01 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -6.02 Mn
Sep 30, 2025 -251,000.00
Jun 30, 2025 -14.57 Mn
Mar 31, 2025 -10.01 Mn
Dec 31, 2024 -7.08 Mn
Sep 30, 2024 31.85 Mn
Jun 30, 2024 -8.86 Mn
Mar 31, 2024 -6.96 Mn
Dec 31, 2023 24.61 Mn
Sep 30, 2023 -10.79 Mn
Jun 30, 2023 12.24 Mn
Mar 31, 2023 -6.91 Mn
Dec 31, 2022 -7.31 Mn
Sep 30, 2022 -23.90 Mn
Jun 30, 2022 -23.91 Mn
Mar 31, 2022 20.26 Mn
Dec 31, 2021 21.24 Mn
Sep 30, 2021 9.07 Mn
Jun 30, 2021 8.67 Mn
Mar 31, 2021 12.39 Mn